Metagenomi, INC

Metagenomi Therapeutics announced full-year 2025 financial results and significant progress in its lead hemophilia A program, MGX-001, targeting clinical trials in 2027.

Metagenomi, Inc. rebrands to Metagenomi Therapeutics, Inc., highlighting its strategic focus on lead gene-editing programs and extending its cash runway into Q4 2027.

Metagenomi announced Q3 2025 financial results, strategic pipeline reprioritization, a 25% workforce reduction, and new leadership, extending its cash runway into Q4 2027.

Metagenomi secured a non-exclusive license for Acuitas LNP technology for a single target while simultaneously terminating its agreement with Affini-T Therapeutics due to Affini-T's insolvency.

Metagenomi, a precision genetic medicines company, reported its second quarter 2025 financial results and provided updates on its gene editing programs, including progress on MGX-001 for hemophilia A and its collaboration with Ionis.

Metagenomi, Inc. announced the results of its 2025 annual meeting of stockholders, where Willard H. Dere, M.D. was elected as a Class I Director and PricewaterhouseCoopers LLP was ratified as the independent auditor for fiscal year 2025.

Metagenomi Therapeutics, Inc. reported a net loss of $23.1 million for the first quarter of 2026, with a decrease in collaboration revenue and operating expenses.

Metagenomi, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, driven by terminated collaboration agreements, while announcing a new CEO and positive preclinical data for its lead hemophilia A program.

Metagenomi, a precision genetic medicines company, reported a significantly wider net loss in the second quarter of 2025 due to a substantial decrease in collaboration revenue, primarily from the termination of its agreement with Moderna, despite progress in its genome editing pipeline.

Metagenomi, a precision gene editing company, announces its Q1 2025 financial results, highlighting progress in its research and development programs and collaborations.

Metagenomi's Q3 2024 report details financial results, pipeline advancements, and strategic shifts, including the termination of the Moderna collaboration and progress in hemophilia A and cardiometabolic programs.

Metagenomi, a precision genetic medicines company, released its second quarter 2024 results, highlighting progress in its therapeutic programs and platform technology.

Metagenomi Therapeutics, Inc. reported an increased net loss in 2025, alongside a strategic reprioritization of its pipeline, a 25% workforce reduction, and an extension of its cash runway into late 2027.

Metagenomi's 2024 10-K filing highlights advancements in its gene editing platform and progress in its lead Hemophilia A program, with plans for IND filings in 2026.

Metagenomi's 10-K filing details its proprietary metagenomics-derived genome editing toolbox and its strategy for developing curative genetic medicines.

Laurence Reid, a Director at Metagenomi Therapeutics, Inc., has acquired stock options, indicating a potential long-term commitment and alignment with the company's future performance.

Metagenomi Therapeutics, Inc. reports that Director Willard H. Dere acquired 21,000 stock options.

Metagenomi Therapeutics, Inc. director Eric Bjerkholt acquired 21,000 stock options with an exercise price of $1.23.

Metagenomi Therapeutics, Inc. reports that Director Juergen Eckhardt acquired 21,000 stock options with an exercise price of $1.23.

Metagenomi Therapeutics, Inc. reports that Chief Financial Officer Pamela Wapnick sold 2,884 shares of common stock on June 5, 2026, to cover tax withholding obligations upon the vesting of restricted stock units.

Metagenomi Therapeutics, Inc. reports on stock transactions involving CEO Jian Irish, including automatic sales for tax withholding and shares held in trusts.

Metagenomi Therapeutics, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 9, 2026, to conduct routine director elections and auditor ratification.

Metagenomi, Inc. has filed a definitive proxy statement with the SEC.

Metagenomi, Inc. will hold its 2025 annual meeting of stockholders virtually on June 10, 2025, to elect a director and ratify the appointment of its independent registered public accounting firm.

Metagenomi, Inc., a precision genetic medicines company, files an amendment to its S-1 registration statement, aiming to raise approximately $100 million in an initial public offering and list its common stock on the Nasdaq Global Select Market under the symbol 'MGX'.

Metagenomi, a precision genetic medicines company, has filed an S-1/A form to register 6,250,000 shares of common stock for an initial public offering, with an expected price between $15.00 and $17.00 per share.